{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:26Z","timestamp":1790882426686,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/wco.0b013e32833c2054","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T09:19:26Z","timestamp":1277457566000},"page":"445-449","source":"Crossref","is-referenced-by-count":19,"title":["Iatrogenic myopathies"],"prefix":"10.1097","volume":"23","author":[{"given":"Frank L","family":"Mastaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210206","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0b013e32830e2774","article-title":"Drug-induced myopathies","volume":"21","author":"Klopstock","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"R2-2-20210206","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp.2008.168294","article-title":"Toxic and drug-induced myopathies","volume":"80","author":"Dalakas","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R3-2-20210206","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bmj.a2286","article-title":"Statin induced myopathy","volume":"337","author":"Sathasivam","year":"2008","journal-title":"BMJ"},{"key":"R4-2-20210206","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"R5-2-20210206","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"key":"R6-2-20210206","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"R7-2-20210206","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clin Ther"},{"key":"R8-2-20210206","doi-asserted-by":"crossref","first-page":"e2522","DOI":"10.1371\/journal.pone.0002522","article-title":"Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991\u20132006","volume":"3","author":"Molokhia","year":"2008","journal-title":"PLoS One"},{"key":"R9-2-20210206","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.1535","article-title":"Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis","volume":"17","author":"McAdams","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R10-2-20210206","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1503\/cmaj.070675","article-title":"The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials","volume":"178","author":"Josan","year":"2008","journal-title":"CMAJ"},{"key":"R11-2-20210206","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1345\/aph.1M410","article-title":"Does simvastatin cause more myotoxicity compared with other statins?","volume":"43","author":"Backes","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R12-2-20210206","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pds.1711","article-title":"Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors","volume":"18","author":"Rowan","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-2-20210206","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","article-title":"Combination statin-fibrate therapy: safety aspects","volume":"11","author":"Franssen","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"R14-2-20210206","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2009.151","article-title":"Myopathy with statin-fibrate combination therapy: clinical considerations","volume":"5","author":"Jacobson","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"R15-2-20210206","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy.","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"R16-2-20210206","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R17-2-20210206","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/tpj.2009.3","article-title":"Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy","volume":"9","author":"Furihata","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"R18-2-20210206","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"R19-2-20210206","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"R20-2-20210206","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"R21-2-20210206","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","article-title":"Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation","volume":"39","author":"Tay","year":"2008","journal-title":"Pediatr Neurol"},{"key":"R22-2-20210206","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur Neurol"},{"key":"R23-2-20210206","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/gm120","article-title":"Pharmacogenomic insights into treatment and management of statin-induced myopathy","volume":"1","author":"Peters","year":"2009","journal-title":"Genome Med"},{"key":"R24-2-20210206","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"R25-2-20210206","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R26-2-20210206","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"R27-2-20210206","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.4049\/jimmunol.180.10.6988","article-title":"Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes","volume":"180","author":"Zhang","year":"2008","journal-title":"J Immunol"},{"key":"R28-2-20210206","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1749-6632.2009.04646.x","article-title":"Influence of statins on MHC class I expression","volume":"1173","author":"Singh","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"R29-2-20210206","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mus.21479","article-title":"Skeletal muscle cell MHC I expression: implications for statin-induced myopathy","volume":"41","author":"Singh","year":"2010","journal-title":"Muscle Nerve"},{"key":"R30-2-20210206","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.107.131615","article-title":"The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins","volume":"324","author":"Madsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R31-2-20210206","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/0192623307311412","article-title":"Rosuvastatin: characterization of induced myopathy in the rat","volume":"36","author":"Westwood","year":"2008","journal-title":"Toxicol Pathol"},{"key":"R32-2-20210206","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.lfs.2008.01.021","article-title":"Role of multidrug resistance-associated protein-1 transporter in statin-induced myopathy","volume":"82","author":"Dorajoo","year":"2008","journal-title":"Life Sci"},{"key":"R33-2-20210206","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1254\/jphs.08238FP","article-title":"Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats","volume":"109","author":"Itagaki","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"R34-2-20210206","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"R35-2-20210206","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","article-title":"Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect","volume":"23","author":"Cao","year":"2009","journal-title":"FASEB J"},{"key":"R36-2-20210206","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Atherosclerosis"},{"key":"R37-2-20210206","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"J Physiol"},{"key":"R38-2-20210206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5551\/jat.E551","article-title":"Investigation of gene expression in C2C12 myotubes following simvastatin application and mechanical strain","volume":"16","author":"Yu","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"R39-2-20210206","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","article-title":"A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle","volume":"1","author":"Laaksonen","year":"2006","journal-title":"PLoS One"},{"key":"R40-2-20210206","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"R41-2-20210206","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5551\/jat.E812","article-title":"Mechanism of statin-induced myopathy investigated using microarray technology","volume":"16","author":"Kohro","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"R42-2-20210206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32 ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"R43-2-20210206","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2008.03448.x","article-title":"Vitamin D insufficiency\u2013a novel mechanism of statin-induced myalgia?","volume":"71","author":"Lee","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R44-2-20210206","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.mehy.2009.10.031","article-title":"Do statins cause myopathy by lowering vitamin E levels Med H","volume":"74","author":"Galli","year":"2010","journal-title":"ypotheses"},{"key":"R45-2-20210206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11936-009-0027-3","article-title":"Management of the statin-intolerant patient","volume":"11","author":"Smiley","year":"2009","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"R46-2-20210206","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u2018pain-free\u2019 statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R47-2-20210206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R48-2-20210206","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"R50-2-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2125.2008.03224.x","article-title":"Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products","volume":"66","author":"Lapi","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R51-2-20210206","first-page":"245","article-title":"\u2018Muscle-sparing\u2019 statins: preclinical profiles and future clinical use","volume":"10","author":"Pfefferkorn","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"R52-2-20210206","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/mus.21091","article-title":"Severe hydroxychloroquine myopathy","volume":"38","author":"Abdel-Hamid","year":"2008","journal-title":"Muscle Nerve"},{"key":"R53-2-20210206","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1212\/WNL.0b013e3181aae814","article-title":"Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy","volume":"73","author":"Pfeffer","year":"2009","journal-title":"Neurology"},{"key":"R54-2-20210206","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.20884","article-title":"Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy","volume":"37","author":"Allen","year":"2008","journal-title":"Muscle Nerve"},{"key":"R55-2-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2008.12.008","article-title":"Interferon alpha and neuromuscular disorders","volume":"207","author":"Stubgen","year":"2009","journal-title":"J Neuroimmunol"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32833c2054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:32:23Z","timestamp":1786041143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-201010000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32833c2054","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}